Meyrat, P; Safroneeva, E; Schoepfer, A M (2012). Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Alimentary pharmacology & therapeutics, 36(11-12), pp. 1084-93. Oxford: Wiley-Blackwell 10.1111/apt.12087
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Meyrat AlimentPharmacolTher 2012.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (368kB) | Request a copy |
While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM) |
UniBE Contributor: |
Safroneeva, Ekaterina |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0269-2813 |
Publisher: |
Wiley-Blackwell |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:35 |
Last Modified: |
05 Dec 2022 14:11 |
Publisher DOI: |
10.1111/apt.12087 |
PubMed ID: |
23066911 |
Web of Science ID: |
000310871000009 |
BORIS DOI: |
10.7892/boris.14037 |
URI: |
https://boris.unibe.ch/id/eprint/14037 (FactScience: 220836) |
Actions (login required)
 |
Edit item |